Doctors worldwide are debating the risk-benefit ratio for immediate sequential bilateral cataract surgery, or ISBCS, vs. performing second eye surgery 1 or more days later.
I recently asked David Harmon at Market Scope for data on the current level of U.S. ophthalmic surgeon adoption of ISBCS. Rounded off for 2021, 9% are performing ISBCS, 13% are considering it, and a whopping 78% currently do not plan to adopt ISBCS. So, we are only at the innovator/early adopter stage for ISBCS.
As I talk with my partners and colleagues, the major (Read more...)
Uncategorized